文献速递肾癌与肾肿瘤

帕唑帕尼二线抗血管生成治疗TKI失败后转移性肾细胞癌的2期试验

Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era.
PubMed 文献 · Eur Urol Oncol · 2019-08-30

这项2期单臂开放标签研究在10个西班牙中心纳入27例一线TKI治疗后进展的mRCC患者,接受帕唑帕尼治疗。客观缓解率为14.8%,中位PFS为6.7个月,中位OS为20.6个月。治疗8周时应答患者的循环IL-10水平较低(p=0.002)。

要点

  • 帕唑帕尼二线治疗TKI失败后mRCC的ORR为14.8%,中位PFS 6.7个月,中位OS 20.6个月。
  • 治疗8周时应答患者循环IL-10水平显著较低(p=0.002),或可预测疗效。
  • 多数患者发生轻中度不良事件(48.1%),44.4%发生严重不良事件。

核心结论

  • 帕唑帕尼在TKI治疗失败的mRCC患者中作为二线治疗具有临床活性且耐受性良好。
  • 循环IL-10水平可能预测帕唑帕尼的疗效。

研究设计与样本

  • 2期、开放标签、单臂研究,在10个西班牙中心开展。
  • 纳入27例一线TKI治疗后疾病进展的mRCC患者,中位年龄62岁,男性占51.9%。
  • 患者接受帕唑帕尼治疗直至疾病进展、死亡或不可耐受毒性。

主要发现

  • 客观总缓解率为14.8%(95%CI 1.4-28.2%)。
  • 中位无进展生存期为6.7个月(95%CI 3.7-11.2),中位总生存期为20.6个月(95%CI 12.6-27.4)。
  • 治疗8周后,应答患者的循环IL-10水平较低(p=0.002)。
  • 中位帕唑帕尼治疗持续时间为6.0个月(范围1.0-47.0)。
  • 48.1%的患者发生轻中度不良事件,44.4%发生严重不良事件。

临床怎么用

  • 在nivolumab和cabozantinib等药物不可及时,帕唑帕尼可作为TKI失败后mRCC的二线治疗选择。
  • 在免疫联合抗血管生成已成为一线选择的背景下,IL-10水平值得进一步探索作为序贯TKI-TKI治疗疗效的预测指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pazopanib is an oral angiogenesis tyrosine kinase inhibitor (TKI) recommended in metastatic renal cell carcinoma (mRCC) for treatment-naïve patients or those experiencing cytokine failure. We conducted a phase 2, open-label, single-arm study in ten Spanish centres among mRCC patients whose disease progressed on first-line TKI. Patients received pazopanib until disease progression, death, or unacceptable toxicity. Twenty-seven patients were included (median age 62yr, 51.9% male). The objective overall response rate was 14.8% (95% confidence interval [CI] 1.4-28.2%). Median progression-free survival was 6.7mo (95% CI 3.7-11.2) and median overall survival was 20.6mo (95% CI 12.6-27.4). Lower circulating levels of IL-10 (p=0.002) were observed in responding patients at 8 wk after treatment. The median pazopanib treatment duration was 6.0mo (range 1.0-47.0). Most patients (48.1%) had mild or moderate adverse events (AEs), while 44.4% had severe AEs. Pazopanib was clinically active and well tolerated as a second-line treatment in mRCC patients after TKI failure, and circulating IL-10 levels could predict response. PATIENT SUMMARY: Pazopanib could be used as a second-line therapy for the treatment of metastatic renal cell carcinoma after failure of tyrosine kinase inhibitor (TKI) therapy when drugs such as nivolumab and cabozantinib are not available. Now that immunotherapy plus antiangiogenic therapy is a first-line option, IL-10 levels deserve further exploration as a potential predictor of response to sequential TKI-TKI therapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bellmunt J, Esteban E, Del Muro XG, et al. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era. Eur Urol Oncol. 2019. PMID: 31477526. doi:10.1016/j.euo.2019.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。